Prospective, non-interventional, observational and multicenter study to investigate the dose, efficacy and safety of perampanel when used as a first adjunct treatment in the routine clinical care of patients older than 1
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: EISAI LTD.
- Execution start: 01/02/2020
- End of execution: 30/04/2022
- IP: JESUS ANTONIO RUIZ GIMENEZ